Verve Therapeutics’ (VERV) “Buy” Rating Reiterated at HC Wainwright

Verve Therapeutics (NASDAQ:VERV)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They presently have a $15.00 target price on the stock. HC Wainwright’s price target indicates a potential upside of 159.52% from the company’s current price.

Several other equities research analysts have also recently weighed in on the stock. Royal Bank of Canada decreased their price objective on shares of Verve Therapeutics from $17.00 to $15.00 and set an “outperform” rating for the company in a research report on Tuesday, March 4th. William Blair reissued an “outperform” rating on shares of Verve Therapeutics in a research report on Friday, February 21st. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $25.50.

Verve Therapeutics Trading Up 4.1 %

Shares of VERV opened at $5.78 on Tuesday. The stock’s 50-day moving average price is $6.96 and its two-hundred day moving average price is $6.09. Verve Therapeutics has a 12 month low of $4.31 and a 12 month high of $13.63. The company has a market capitalization of $513.24 million, a PE ratio of -2.35 and a beta of 1.77.

Verve Therapeutics (NASDAQ:VERV) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.58) EPS for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.14. The company had revenue of $13.08 million for the quarter, compared to analyst estimates of $3.94 million. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%. Equities research analysts predict that Verve Therapeutics will post -2.49 EPS for the current fiscal year.

Hedge Funds Weigh In On Verve Therapeutics

Institutional investors have recently made changes to their positions in the stock. GAMMA Investing LLC increased its position in Verve Therapeutics by 189.7% in the 4th quarter. GAMMA Investing LLC now owns 6,054 shares of the company’s stock valued at $34,000 after buying an additional 3,964 shares in the last quarter. IFP Advisors Inc raised its position in shares of Verve Therapeutics by 823,700.0% during the fourth quarter. IFP Advisors Inc now owns 8,238 shares of the company’s stock worth $47,000 after purchasing an additional 8,237 shares during the period. BNP Paribas Financial Markets bought a new position in shares of Verve Therapeutics in the 4th quarter worth $50,000. Erste Asset Management GmbH acquired a new stake in Verve Therapeutics in the 3rd quarter valued at $56,000. Finally, Impact Partnership Wealth LLC acquired a new stake in Verve Therapeutics in the 4th quarter valued at $70,000. Institutional investors and hedge funds own 97.11% of the company’s stock.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.